NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
Clinical Trials
5 trialsNCT00511459 2015-10-29
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Amgen
Phase 2 Completed
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT00752570 2015-09-02
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Amgen
Phase 2 Completed
NCT00102830 2010-08-20
Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors
Amgen
Phase 1 Completed